Ingevity Corporation NGVT has expanded its Capa caprolactone distribution network by selecting Ultrapolymers Group as the distributor for Capa Bioplastics in Europe. Ultrapolymers will use its expertise in sales and technical teams across Europe to increase the sales of Ingevity's Capa Bioplastics products. The addition of a new distribution partner in Europe devoted to Ingevity's Capa biodegradable thermoplastics allows the company to better service its customers in the region. Ultrapolymers' network of compounders and converters, as well as its technical competence and customer service, are consistent with Ingevity's growth strategy in Europe. Ingevity's array of Capa caprolactone bioplastics is in sync with Ultrapolymers' objective of providing customers with the most advanced, innovative and sustainable materials. Shares of Ingevity have lost 31.7% over the past year compared with a 15.2% decline of its industry. Zacks Investment Research Image Source: Zacks Investment Research Ingevity, in February 2019, completed the purchase of the Capa caprolactone division of Perstorp Holding AB for roughly $652.5 million. Capa is an international market leader in the manufacture and commercialization of caprolactone and high-value downstream derivatives. The division’s products are crucial components in coatings, adhesives, elastomers, bioplastics and resins. The company, on its first-quarter call, said that it sees its sales for 2024 in the band of $1.4-$1.55 billion and adjusted EBITDA in the range of $365-$390 million. Zacks Rank & Key Picks Ingevity currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the basic materials space include Carpenter Technology Corporation CRS, Eldorado Gold Corporation EGO and Kronos Worldwide, Inc. KRO. Carpenter Technology currently carries a Zacks Rank #1 (Strong Buy). CRS beat the Zacks Consensus Estimate in each of the last four quarters, with the average earnings surprise being 15.1%. The company's shares have soared 92.7% in the past year. You can see the complete list of today's Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Eldorado’s current-year earnings is pegged at $1.09 per share, indicating a year-over-year rise of 91.2%. EGO, a Zacks Rank #1 stock, beat the consensus estimate in each of the last four quarters, with the average earnings surprise being 430.7%. The company's shares have rallied roughly 56.2% in the past year. Kronos Worldwide currently carries a Zacks Rank #1. KRO has a projected earnings growth rate of 297.7% for the current year. The company’s shares have rallied around 37% in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Carpenter Technology Corporation (CRS):Free Stock Analysis Report Kronos Worldwide Inc (KRO):Free Stock Analysis Report Eldorado Gold Corporation (EGO):Free Stock Analysis Report Ingevity Corporation (NGVT):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Ingevity (NGVT), Ultrapolymers Tie-Up for Capa Bioplastics Sales
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...